etravirine has been researched along with plx4032 in 1 studies
| Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
|---|---|---|---|---|---|
| 572 | 90 | 321 | 1,657 | 103 | 1,587 |
| Protein | Taxonomy | etravirine (IC50) | plx4032 (IC50) |
|---|---|---|---|
| Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Converso, A; Daublain, P; El Marrouni, A; Kesisoglou, F; Lipert, MP; Templeton, AC; Wuelfing, WP | 1 |
1 other study(ies) available for etravirine and plx4032
| Article | Year |
|---|---|
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Discovery; Humans; Oral Mucosal Absorption; Pharmaceutical Preparations; Solubility | 2022 |